Stockscreener 앱 받기
0.2211
5.75%
-0.0135
전일 마감가:
$0.2346
열려 있는:
$0.2122
하루 거래량:
287.95K
Relative Volume:
0.13
시가총액:
$26.35M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-13.16%
1개월 성능:
-25.47%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.2122
$0.2399
1주일 범위
$0.21
$0.25
52주 변동 폭
$0.205
$6.43
Pomdoctor Ltd Adr Stock (POM) Company Profile
Compare POM vs HITI, PETS, WGRX, SCNX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
POM
Pomdoctor Ltd Adr
|
0.2211 | 27.96M | 0 | 0 | 0 | 0.00 |
|
HITI
High Tide Inc
|
2.49 | 210.82M | 376.07M | -22.41M | 18.73M | -0.298 |
|
PETS
Petmed Express Inc
|
2.95 | 64.42M | 270.52M | -6.08M | 17.42M | -0.2944 |
|
WGRX
Wellgistics Health Inc
|
0.2275 | 26.22M | 28.99M | -39.20M | -3.34M | 0.00 |
|
SCNX
Scienture Holdings Inc
|
0.4005 | 16.70M | 0 | 0 | 0 | 0.00 |
Pomdoctor Ltd Adr 주식(POM)의 최신 뉴스
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against PomDoctor and Vistagen and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
ROSEN, A HIGHLY RANKED LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against PomDoctor, Ltd. (NASDAQ: POM) - ChartMill
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
POM INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Pomdoctor (POM) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Shareholders who lost money in American Depositary Receipts of PomDoctor, Ltd. (NASDAQ: POM) Should Contact Wolf Haldenstein Immediately - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in PomDoctor Ltd. of Class Action Lawsuit and Upcoming Deadlines – POM - ChartMill
ROSEN, LEADING INVESTOR COUNSEL, Encourages PomDoctor Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Shareholders who lost money in American Depositary Receipts - GlobeNewswire
POM Investors Have Opportunity to Lead PomDoctor Ltd. Securities Fraud Lawsuit - Barchart.com
POM SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Pomdoctor (POM) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
POM Stockholder Alert: Robbins LLP Reminds Investors of the Class Action Against POMDoctor Ltd. - Barchart.com
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the POMDoctor Ltd. Securities Class Action Lawsuit - ChartMill
Rosen Law Firm Urges PomDoctor Ltd. (NASDAQ: POM) Stockholders to Contact the Firm for Information About Their Rights - ChartMill
Pomdoctor Deepens Medical Insurance Integration to Expand Online Chronic-Care Reach Across Major Chinese Cities - TipRanks
POM SHAREHOLDER ACTION: Faruqi & Faruqi, LLP Reminds Pomdoctor (POM) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
Pomdoctor Receives Nasdaq Deficiency Notice Over Minimum Bid Price - TipRanks
Pomdoctor expands online hospital business through pharma partnerships By Investing.com - Investing.com India
Pomdoctor Deepens Pharma Partnerships to Drive Internet Hospital Expansion in China - TipRanks
United States shares higher at close of trade; Dow Jones Industrial Average up 1.05% - Investing.com India
U.S. shares higher at close of trade; Dow Jones Industrial Average up 1.05% - Investing.com UK
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.05% - Investing.com
Pomdoctor (POM) Losses Persist as Price-to-Sales Premium Tests Bullish Scaling Narrative - Sahm
Pomdoctor Limited Reports Strong Revenue Growth Amidst Challenging Conditions - TipRanks
Legence, Cidara Therapeutics, Avadel Pharmaceuticals, Omeros And Other Big Stocks Moving Higher On Friday - Benzinga
Citi (NYSE: C) extends Token Services in Dublin with Euro transfers, 24/7 liquidity - Stock Titan
Citi (NYSE: C) lowers base lending rate to 7.00%, effective Oct 30 at Citibank, N.A. - Stock Titan
Diluted shares outstanding of PomDoctor Ltd. Unsponsored ADR – BOATS:POM - TradingView
Citi Appointed as Depositary Bank for POMDOCTOR LIMITED’s ADR Program - The AI Journal
Citigroup (NYSE:C) Stock Quote - FinancialContent
Free cash flow per share of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
Citigroup Reports Third Quarter 2025 Results - Business Wire
Q3 2025 Results: Citigroup Reports Results; Webcast & Conference Call at 11 a.m. ET Today - Stock Titan
Earnings calendar for: - Yahoo
$0.60 Quarterly Dividend: Citigroup to Pay Nov 26; Multiple Preferred Series Payments Announced - Stock Titan
Debt to assets ratio of PomDoctor Ltd. Unsponsored ADR – BOATS:POM - TradingView
Gross margin % of PomDoctor Ltd. Unsponsored ADR – BOATS:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Balance Sheet – BOATS:POM - TradingView
Operating margin % of PomDoctor Ltd. Unsponsored ADR – BOATS:POM - TradingView
Diluted earnings per share (Diluted EPS) of PomDoctor Ltd. Unsponsored ADR – BOATS:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Income Statement – BOATS:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Statistics – BOATS:POM - TradingView
Diluted net income available to common stockholders of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Financial Statements – BOATS:POM - TradingView
EBIT of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
Diluted earnings per share (Diluted EPS) of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
Total assets of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Earnings and Revenue – BOATS:POM - TradingView
PomDoctor Ltd. Unsponsored ADR Revenue Breakdown – BOATS:POM - TradingView
Gross profit of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
Operating expenses (excl. COGS) of PomDoctor Ltd. Unsponsored ADR – NASDAQ:POM - TradingView
Pomdoctor Ltd Adr (POM) 재무 분석
Pomdoctor Ltd Adr (POM)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
11.24%
3.75%
자본화:
|
볼륨(24시간):